SEARCH

SEARCH BY CITATION

References

  • 1
    Evans AM. Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996; 36: 7S15S.
  • 2
    Patrono C, Rocca B. Nonsteroidal anti inflammatory drugs: past, present, and future. Pharmacol Res 2009; 59: 285289.
  • 3
    Hao H et al. Enantioselective pharmacokinetics of ibuprofen and involved mechanisms. Drug Metab Rev 2005; 1: 215234.
  • 4
    Kean WF et al. Therapeutics of ibuprofen in rheumatic and other chronic and painful diseases. In: Rainsford KD, ed. Ibuprofen: A Critical Bibliographic Review. London: Taylor and Francis, 1999: 277354.
  • 5
    Rainsford KD. History and development of ibuprofen. In: Rainsford KD, ed. Ibuprofen: A Critical Bibliographic Review. London: Taylor and Francis, 1999: 124.
  • 6
    Adams SS. The propionic acids: a personal perspective. J Clin Pharmacol 1992; 32: 317323.
  • 7
    Buckwalter JA, Martin JA. Osteoarthritis. Adv Drug Deliv Rev 2006; 58: 150167.
  • 8
    Denisov LN et al. Role of obesity in the development of osteoarthritis and concomitant diseases. Ter Arkh 2010; 82: 3437.
  • 9
    Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275342.
  • 10
    World Health Organization. 2005). Essential medicines: WHO Model List, 14 ed. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/.
  • 11
    Higton F. The pharmaceutics of ibuprofen. In: Rainsford KD, ed. Ibuprofen: A Critical Bibliographic Review. London: Taylor and Francis, 1999: 5386.
  • 12
    Jamali F et al. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci 1992; 81: 221225.
  • 13
    Brocks DR, Jamali F. The pharmacokinetics of ibuprofen in humans and animals. In: Rainsford KD, ed. Ibuprofen: A Critical Bibliographic Review. London: Taylor and Francis, 1999: 87142.
  • 14
    Day RO et al. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 1988; 43: 480487.
  • 15
    Cox SR et al. Pharmacokinetics of the R(-) and S(-) enantiomers of ibuprofen in the serum and synovial fluid of arthritis patients. J Clin Pharmacol 1991; 31: 8894.
  • 16
    Schneider HT et al. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br J Clin Pharmacol 1990; 29: 127131.
  • 17
    Rudy AC et al. Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Ther Drug Monit 1992; 14: 464470.
  • 18
    Hamman MA et al. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54: 3341.
  • 19
    Suri A et al. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther 1997; 35: 18.
  • 20
    University of British Columbia. Therapeutics initiative: evidence-based drug therapy. Therapeutics Letter, January/February 2001. Available at http://www.ti.ubc.ca.
  • 21
    Buchanan WW, Kean WF. Osteoarthritis IV: clinical therapeutic trials and treatment. Inflammopharmacology 2002; 10: 75149.
  • 22
    Wilhelmsen L et al. Comparison between participants in primary preventative trials. J Chronic Dis 1976; 29: 331339.
  • 23
    Bellamy N, Buchanan WW. Clinical evaluation in rheumatic diseases. In: Koopman WJ, ed. Arthritis and Allied Conditions. A Textbook of Rheumatology, 13th. 1, Baltimore, MD: Williams and Wilkins, 1997: 4779.
  • 24
    Easterbrook PJ et al. Publication bias in clinical research. Lancet 1991; 337: 867872.
  • 25
    Kean WF et al. Osteoarthritis: symptoms, signs, and source of pain. Inflammopharmacology 2004; 12: 331.
  • 26
    Downie RS, Macnaughton J. Clinical Judgement. Evidence in Practice. Oxford: Oxford University Press, 2000.
  • 27
    Bellamy N. WOMAC Osteoarthritis Index: A User's Guide. London, ON: University of Western Ontario, 1995.
  • 28
    Puopolo A et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 2007; 15: 13481356.
  • 29
    Wiesenhutter CW et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 470479.
  • 30
    Ehrich EW et al. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities Osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27: 26352641.
  • 31
    Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol 2004; 31: 13731783.
  • 32
    Day R et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 17811787.
  • 33
    Bliddal H et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis Cartilage 2000; 8: 912.
  • 34
    Sacchetti G et al. Clinical testing of indoprofen in osteoarthritis: a controlled trial using a balanced incomplete block design. Curr Ther Res 1978; 24: 274283.
  • 35
    Christgau S et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 209215.
  • 36
    Gineyts E et al. Urinary excretion of glucosyl galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology 2001; 40: 315321.
  • 37
    Gineyts E et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004; 63: 857861.
  • 38
    Trnavský K et al. Efficacy and safety of 5% ibuprofen cream treatment in knee osteoarthritis. Results of a randomized, double-blind, placebo-controlled study. J Rheumatol 2004; 3: 565572.
  • 39
    Rovenský J et al. Treatment of knee osteoarthritis with a topical non-steroidal antiinflammatory drug. Results of a randomized, double-blind, placebo-controlled study on the efficacy and safety of a 5% ibuprofen cream. Drugs Exp Clin Res 2001; 27: 209221.
  • 40
    Cross PL et al.; TOIB Study Team. TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. [ISRCTN79353052]. BMC Musculoskelet Disord 2005; 6: 55.
  • 41
    Carnes D et al. TOIB study team. Influences on older people's decision making regarding choice of topical or oral NSAIDs for knee pain: qualitative study. Br Med J 2008; 336: 142145.
  • 42
    Underwood M et al.; TOIB study team. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. Br Med J 2008; 336: 138142.
  • 43
    Underwood M et al. Topicalor oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess 2008; 12: iiiiiv. ix-155.
  • 44
    Castelnuovo E et al.; TOIB study team. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052]. Rheumatology 2008; 47: 10771081.
  • 45
    Buchanan WW, Kean WF. Evidence-based medicine: the median is not the message. J Rheumatol 2001; 28: 23712372.
  • 46
    Buchanan WW, Kean WF. Clinical judgement and evidence based medicine. Joint Bone Spine 2001; 68: 370372.